NL-OMON19866尚未招募不适用
COBRA treat-to-target trial
VU University Medical Center0 个研究点目标入组 190 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 190
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) RA according to the 2010 classification criteria of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR)
- •2) Age of 18 years and older
排除标准
- •- Prior treatment DMARDs (except hydroxychloroquine)
- •- Insulin-dependent Diabetes mellitus
研究者
相似试验
已完成
不适用
COBRA treat-to-target trialrheumatoid arthritisRA1000381610023213NL-OMON44989Vrije Universiteit Medisch Centrum190
进行中（未招募）
1 期
COBRA-KAI study: COVID-19 vaccination in patients with a hematological diseaseEUCTR2021-001072-41-NLAmsterdam UMC location VUmc850
已完成
不适用
COBRA-KAI study: COVID-19 vaccination in patients with reduced B-cell and T-cell immunity: response after vaccination of a kaleidoscopic group hematological patients, what*s the impact?hematological malignanciesreduced B-cell and T-cell immunityreduced immunity10047954NL-OMON51241Vrije Universiteit Medisch Centrum723
进行中（未招募）
1 期
Clinical trial to assess the efficacy of Plasma Rich in Growth Factors (PRGF®) in the treatment of vulvar lichen sclerosus atrophicusVulvar Lichen Sclerosus et atrophicusEUCTR2021-006474-23-ESBTI I MAS D S.L.30
进行中（未招募）
1 期
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic DermatitisDermatitis atopicMedDRA version: 20.0Level: PTClassification code: 10012438Term: Dermatitis atopic Class: 100000004858CTIS2023-504869-23-00AbbVie Deutschland GmbH & Co. KG438